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Abstract
Background & Aims: Upregulation of hepatic delta- aminolevulinic acid synthase 1 
with accumulation of potentially toxic heme precursors delta- aminolevulinic acid 
and porphobilinogen is fundamental to the pathogenesis of acute hepatic porphyria. 
Aims: evaluate long- term efficacy and safety of givosiran in acute hepatic porphyria.
Methods: Interim analysis of ongoing ENVISION study (NCT03338816), after all ac-
tive patients completed their Month 24 visit. Patients with acute hepatic porphyria 
2  |     VENTURA ET Al
1  | INTRODUC TION
Acute hepatic porphyria (AHP) is a family of four rare genetic dis-
eases characterized by potentially life- threatening acute attacks 
and, for some patients, chronic manifestations impacting daily func-
tioning and quality of life (QOL).1- 4 The AHP types are acute inter-
mittent porphyria (AIP; most common), variegate porphyria (VP), 
hereditary coproporphyria (HCP), and delta- aminolevulinic acid 
(ALA) dehydratase– deficiency porphyria.2,5 Clinical manifestations 
are due to pathogenic mutations leading to deficiency in an enzyme 
of hepatic heme biosynthesis.6 These defects predispose for trigger-
ing factors inducing delta- aminolevulinic acid synthase 1 (ALAS1), 
the initial and normally rate- controlling enzyme of the heme biosyn-
thesis pathway7,8; trigger factors may lead to further induction of 
ALAS1.9 In AHP, this can lead to accumulation of the potentially toxic 
porphyrin precursors ALA and porphobilinogen (PBG), thought to be 
causal for disease manifestations, as well as porphyrins.9- 11
The most severe symptoms of AHP occur during acute neurovis-
ceral attacks, which manifest most commonly as severe abdominal 
pain, nausea, vomiting, tachycardia, hypertension, hyponatraemia, 
mental status changes, muscle weakness, and change in urine co-
lour to red/brown.1,3,4,12 Attacks often require hospitalization and, 
without prompt treatment, can result in paralysis, respiratory 
failure, and, rarely, permanent neurologic deficits or death.4,13,14 
Approximately 3% to 8% of symptomatic patients with AIP experi-
ence recurrent attacks (≥4 attacks/year).13,15,16 Some patients also 
experience debilitating chronic symptoms between attacks, such as 
pain, fatigue, and nausea.4,17 Long- term complications and comor-
bidities related to AHP can include chronic kidney disease (CKD), 
fixed systemic arterial hypertension, chronic neuropathy, and liver 
disease (including aminotransferase elevations, fibrosis, cirrhosis, 
and hepatocellular carcinoma).3-5,16,18-21
Prior to the approval of givosiran, treatment options were limited, 
and disease management focused on avoidance of attack triggers and 
use of intravenous (IV) glucose or hemin for attacks.12 For patients expe-
riencing recurrent attacks, the impact of the disease can be severe4,17; 
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(≥12 years) with recurrent attacks received givosiran (2.5 mg/kg monthly) (n = 48) or 
placebo (n = 46) for 6 months (double- blind period); 93 received givosiran (2.5 mg or 
1.25 mg/kg monthly) in the open- label extension (continuous givosiran, n = 47/48; 
placebo crossover, n = 46/46). Endpoints included annualized attack rate, urinary 
delta- aminolevulinic acid and porphobilinogen levels, hemin use, daily worst pain, 
quality of life, and adverse events.
Results: Patients receiving continuous givosiran had sustained annualized attack rate 
reduction (median 1.0 in double- blind period, 0.0 in open- label extension); in pla-
cebo crossover patients, median annualized attack rate decreased from 10.7 to 1.4. 
Median annualized days of hemin use were 0.0 (double- blind period) and 0.0 (open- 
label extension) for continuous givosiran patients and reduced from 14.98 to 0.71 for 
placebo crossover patients. Long- term givosiran led to sustained lowering of delta- 
aminolevulinic acid and porphobilinogen and improvements in daily worst pain and 
quality of life. Safety findings were consistent with the double- blind period.
Conclusions: Long- term givosiran has an acceptable safety profile and significantly 
benefits acute hepatic porphyria patients with recurrent attacks by reducing attack 
frequency, hemin use, and severity of daily worst pain while improving quality of life.
K E Y W O R D S
Acute hepatic porphyria, ALA synthase- 1, givosiran, health- related quality of life, RNAi 
therapeutics
Lay Summary
Acute hepatic porphyria is a rare genetic disease that in-
volves potentially life- threatening acute attacks and, for 
some patients, persistent symptoms impacting their ability 
to perform daily activities. In this evaluation of information 
compiled from the ongoing ENVISION study, long- term 
givosiran treatment benefited acute hepatic porphyria 
patients with repeated attacks by reducing the number of 
attacks, hemin use, and daily pain while improving qual-
ity of life. Long- term givosiran use is safe and effective for 
patients with acute hepatic porphyria who experience re-
peated attacks.
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management may include prophylactic hemin, and, rarely, liver trans-
plantation has been used as the treatment of last resort.6,22 Hemin 
treatment carries the risk of adverse events (AEs), both acute (eg, head-
ache, phlebitis) and chronic (eg, iron overload, venous thrombosis, ve-
nous obliteration, and central venous catheter complications).5,10,12,23
Givosiran is a subcutaneously administered RNA interference 
therapeutic approved for the treatment of AHP in adults (USA, 
Brazil, Canada),24- 26 and in adults and adolescents aged 12 years 
and older (European Economic Area, United Kingdom, Switzerland, 
Japan).27 Targeting messenger RNA (mRNA) encoding ALAS1, giv-
osiran lowers induced ALAS1, thereby preventing accumulation of 
ALA and PBG.28- 31 Clinical studies have demonstrated that givosiran 
treatment leads to sustained lowering of urinary ALAS1 mRNA, ALA 
and PBG levels, and, in patients experiencing recurrent attacks, re-
duces the annualized attack rate (AAR) compared with placebo.30,32
Givosiran treatment for 6 months during the double- blind period 
of the randomized, placebo- controlled, phase 3 study in 94 patients 
with AHP and recurrent attacks (ENVISION) led to reductions in por-
phyria attack rate, hemin usage, ALA and PBG levels, and daily worst 
pain compared with placebo.28 Patients treated with givosiran also 
showed improvement in QOL and patient- reported outcomes. After 
the double- blind period, all on- study patients received givosiran 
during the open- label extension (OLE) period, which aims to assess 
the long- term efficacy and safety of givosiran in patients with AHP. 
Here we report interim data from the patients in ENVISION who 
completed at least 24 months on study.
2  | MATERIAL S AND METHODS
2.1 | Study design and patients
ENVISION (NCT03338816) is a 36- month study evaluating the 
efficacy and safety of givosiran in patients with AHP: a 6- month, 
double- blind, randomized, placebo- controlled period,28 and a 30- 
month OLE period. The present analysis reflects cumulative efficacy 
and safety data as of the data cutoff date of June 24, 2020, at which 
time all active patients had at least completed the Month 24 visit. 
Eligible patients were aged ≥12 years with a documented diagnosis 
of AHP and a confirmed AHP genetic mutation or biochemical and 
clinical criteria consistent with AHP, had ≥2 porphyria attacks (re-
quiring hospitalization, urgent healthcare visit, or treatment with IV 
hemin at home) within the 6 months prior to baseline, and agreed 
to discontinue prophylactic hemin (hemin only permitted for acute 
attacks). During the double- blind period, patients were randomized 
(1:1) to monthly givosiran (2.5 mg/kg) or placebo for 6 months.
Patients entering the 30- month OLE received subcutaneous gi-
vosiran 2.5 or 1.25 mg/kg monthly through Month 12 (Figure S1). 
The lower dose was introduced in a protocol amendment to assess 
efficacy and safety. Those enrolled before the amendment received 
2.5 mg/kg; therefore, dose allocation in the OLE was not balanced. 
Patients receiving 1.25 mg/kg who experienced inadequate disease 
control could revert to 2.5 mg/kg at or after the Month 13 visit. In 
a further protocol amendment, all patients remaining on the lower 
dose with no clinically relevant transaminase elevations had their 
doses increased to 2.5 mg/kg. The study was approved by central 
and local institutional review boards or ethics committees and was 
conducted in accordance with Good Clinical Practice guidelines and 
the provisions of the Declaration of Helsinki. All patients provided 
written informed consent.
2.2 | Outcome measures and safety assessments
Efficacy assessments including AAR of composite porphyria attacks 
(defined as attacks requiring hospitalization, urgent healthcare visit, or 
IV hemin administration at home and hereinafter referred to as “com-
posite attacks” or “attacks”), annualized days of hemin use, and urinary 
levels of ALA and PBG were collected throughout the study. Patient- 
reported outcomes included daily worst pain, fatigue, and nausea 
(Figure S2),33,34 opioid use, changes from baseline in the 12- Item 
Short Form Health Survey Version 2 (SF- 12v2) scores,35 EuroQOL- 5 
Dimension (EQ- 5D), Patient Global Impression of Change (PGIC), and 
Porphyria Patient Experience Questionnaire (PPEQ) (Figures S3, S4, 
and S5). Data for daily worst pain, fatigue, nausea, opioid use, and PGIC 
were collected through Month 12. Safety assessments included moni-
toring of AEs, clinical laboratory measures, vital signs, 12- lead electro-
cardiography, and physical examination and were done throughout the 
study. Adverse events were coded according to the Medical Dictionary 
for Regulatory Activities Version 23.0.
2.3 | Statistical analysis
This 24- month interim analysis was conducted using data with a cutoff 
date of June 24, 2020, when all active study patients had completed 
their Month 24 visit. Efficacy and patient- reported outcomes were 
Key points
• After a 6- month double- blind period, 93 patients with 
acute hepatic porphyria and recurrent attacks received gi-
vosiran in the 30- month open- label extension period (con-
tinuous givosiran, n=47/48; placebo crossover, n=46/46); 
data from the 24- month interim analysis are reported here.
• Continuous givosiran patients had sustained annualized 
attack rate reduction; in placebo crossover patients, me-
dian annualized attack rate decreased from 10.7 (double- 
blind period) to 1.4 (open- label extension period).
• Long- term givosiran treatment led to sustained lowering 
of delta- aminolevulinic acid and porphobilinogen and 
improvements in daily worst pain and patient- reported 
assessments of quality of life.
• Long- term givosiran treatment was well tolerated.
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analysed according to whether patients received givosiran in the double- 
blind period before receiving givosiran in the OLE (continuous givosiran 
group) or received placebo in the double- blind period and crossed over 
to givosiran in the OLE (placebo crossover group). Analyses of efficacy 
outcomes were descriptive. Safety assessments were analysed in all pa-
tients who received at least one dose of givosiran; cumulative safety 
data from first dose of givosiran through June 24, 2020 were reported.
3  | RESULTS
3.1 | ENVISION population
Of 94 patients enrolled in the double- blind period, 89 had AIP, two 
had VP, one had HCP, and two had AHP without identified muta-
tions. Of the 48 patients randomized to receive givosiran in the 
double- blind period, 47 entered the OLE (continuous givosiran 
group). One patient with VP did not enter the OLE due to abnor-
mal liver function tests and treatment discontinuation (discussed in 
Safety section). All 46 patients randomized to receive placebo in the 
double- blind period entered the OLE and began givosiran treatment 
(placebo crossover group). In the OLE, 37 patients received givosiran 
1.25 mg/kg monthly (n = 20 in the continuous givosiran group and 
n = 17 in the placebo crossover group), and 56 patients received gi-
vosiran 2.5 mg/kg monthly (n = 27 in the continuous givosiran group 
and n = 29 in the placebo crossover group). Of the 37 patients who 
initially received 1.25 mg/kg monthly in the OLE, 18 experienced 
inadequate disease control (n = 9 in the continuous givosiran group 
and n = 9 in the placebo crossover group) and received 2.5 mg/kg at 
or after the Month 13 visit. All patients remaining on the lower dose 
received 2.5 mg/kg following a subsequent protocol amendment 
(approximately half of these escalations occurred after the data cut-
off date of June 24, 2020) (Figure S1). Continuous givosiran and pla-
cebo crossover groups were generally well balanced with respect to 
baseline demographic and clinical characteristics (Table 1).
At data cutoff, 10 patients had discontinued treatment and 
7 patients had withdrawn from the study (Figure S1); overall, 87 
givosiran- treated patients remained in the study. Primary reasons 
for treatment discontinuation were AEs (n = 4, 1 in the double- blind 
period and 3 in the OLE), pregnancy (n = 1), noncompliance with 
study drug (n = 1), and participant decision (n = 4).
As of June 24, 2020, overall median exposure to givosiran was 22.2 
(range, 1.8- 30.4) months (1 month = 30.44 days), with a cumulative ex-
posure of 164.0 person- years. A total of 89, 87, 75, 28, and 2 patients 
received givosiran for ≥6, ≥12, ≥18, ≥24, and ≥30 months, respectively.
3.2 | Efficacy
3.2.1 | Annualized attack rate and hemin use
Long- term treatment with givosiran led to sustained AAR reduc-
tion (Figure 1A). Patients in the continuous givosiran group had a 
sustained AAR reduction (median AAR 1.00 and 0.00 during the 
double- blind and OLE periods, respectively). In the placebo crosso-
ver group, median AAR decreased from 10.65 in the double- blind 
period to 1.35 in the OLE. During givosiran treatment, median AAR 
was 0.46 and 1.35 in the continuous givosiran and placebo crossover 
groups, respectively, and 0.63 in all givosiran patients. The propor-
tion of patients with zero composite attacks per 3- month interval 
increased during the OLE compared with the double- blind period 
from 67% at Month >3 to 6 to 83% at Month >21 to 24 (continu-
ous givosiran group) and from 24% to 76% (placebo crossover group) 
(Figure 1B).
Long- term givosiran treatment was associated with a sustained 
reduction in hemin use (Figure 1C). In the continuous givosiran group, 
median annualized days of hemin use were 0.00 during the double- 
blind period (0- 6 months) and 0.00 during the OLE (>6 months). 
From baseline until the data cutoff date (double- blind + OLE peri-
ods), overall median annualized days of hemin use across all patients 
treated with givosiran was 0.44 day per year. The proportion of pa-
tients with zero days of hemin use increased during the OLE com-
pared with the double- blind period (Figure 1D) and reached ≥93% 
in both the placebo crossover and continuous givosiran groups by 
Month 27 in the OLE period (Figure 1E). In the continuous givosiran 
group, 68% of patients did not require hemin during the OLE. In the 
placebo crossover group, 49% of patients had zero days of hemin 
use during the OLE compared with 26% in the double- blind period.
3.2.2 | Patient- reported outcomes and 
patient experience
Patients in the continuous givosiran group reported a further de-
crease in daily worst pain during the OLE (median changes from 
baseline score of 2.29 in daily worst pain were −0.34 and −0.77 in 
the double- blind period and OLE period Month 6 to Month 12, re-
spectively). Placebo crossover patients also reported a decrease in 
daily worst pain in the OLE compared with the double- blind period 
(median changes from baseline score of 3.50 in daily worst pain were 
+0.10 in the double- blind period and −0.54 in the OLE). Decreases in 
the number of patients (67% vs 83%) and median proportion of days 
(5.7 vs 8.5) with opioid use were reported in the placebo crossover 
group during the OLE compared with the double- blind period. No 
changes were observed in patient- reported scores for fatigue and 
nausea.
At Month 24, patients with long- term treatment with givosiran 
showed further improvement in physical and mental health, as as-
sessed by the SF- 12 Physical Component Summary (PCS), Mental 
Component Summary (MCS), and individual domain scores, all 
of which increased compared with Month 6 in both the contin-
uous givosiran and placebo crossover groups (SF- 12v2 survey; 
Figures S6A and S6B). Givosiran treatment also further improved 
QOL assessed by the EuroQol- visual analog scale element of the 
EQ- 5D during the 24- month OLE (Figure S7). Patient- rated overall 
status (PGIC; Figure S8) was assessed until 12 months; the majority 
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of patients in the continuous givosiran group reported improve-
ment in overall status since study commencement at Months 6 
and 12; placebo crossover patients had similar improvements at 
Month 12 compared with givosiran patients at Month 6. Long- 
term treatment with givosiran was associated with improvement 
in activities of daily living, perception of treatment, and living a 
more normal life, with improvements at 24 months seen in both 
the continuous givosiran and placebo crossover groups (PPEQ; 
Figures S9A and S9B).
3.2.3 | Pharmacodynamics
Long- term givosiran treatment led to a sustained lowering of me-
dian urinary ALA and PBG to near- normal levels in the continuous 
givosiran group, and a >75% reduction in the placebo crossover 
group during the OLE (Figures 2A and B). At baseline during the 
double- blind period, mean urinary ALAS1 mRNA expression was 
similar in the placebo and givosiran groups (2.21 and 2.66, respec-
tively). At Month 6, mean ALAS1 mRNA was reduced by 58% in 








Age at screening, years, median (range) 36.0 (20, 60) 42.0 (19, 65) 37.5 (19, 65)
Female, n (%) 41 (89) 43 (90) 84 (89)
Race, n (%)
Caucasian 34 (74) 39 (81) 73 (78)
Black/African American 1 (2) 0 (0) 1 (1)
Asian 7 (15) 8 (17) 15 (16)
Other 4 (9) 1 (2) 5 (5)
AIP, n (%) 43 (93) 46 (96) 89 (95)
Non- AIP,a n (%) 3 (7) 2 (4) 5 (5)
HCP 0 (0) 1 (2) 1 (1)
VP 1 (2) 1 (2) 2 (2)
AHP without an identified mutationb 2 (4) 0 (0) 2 (2)
Years since diagnosis, median (range) 6.46 (0.1, 38.5) 6.98 (0.2, 43.3) 6.55 (0.1, 43.3)
Prior hemin prophylaxis, n (%) 18 (39) 20 (42) 38 (40)
Historical AAR,c median (range) 7.0 (0,d 46) 8.0 (4, 34) 8.0 (0,d 46)
Prior chronic symptoms,e n (%) 26 (57) 23 (48) 49 (52)
Prior chronic opioid use,f n (%) 13 (28) 14 (29) 27 (29)
Baseline urinary ALA (mmol/mol Cr), median (range) 16.4 (1.4, 41.5) 16.4 (1.8, 88.9) 16.4 (1.4, 88.9)
Baseline urinary PBG (mmol/mol Cr), median (range) 39.3 (3.6, 87.7) 39.6 (0.4, 150.0) 39.6 (0.4, 150.0)
Neuropathy, n (%) 16 (35) 20 (42) 36 (38)
Sensory 8 (17) 10 (21) 18 (19)
Motor 8 (17) 13 (27) 21 (22)
Autonomic 3 (7) 0 3 (3)
Note: AAR, annualized rate of composite porphyria attacks; AHP, acute hepatic porphyria; AIP, acute intermittent porphyria; ALA, delta- 
aminolevulinic acid; Cr, creatinine; HCP, hereditary coproporphyria; IV, intravenous; OLE, open- label extension; PBG, porphobilinogen; VP, variegate 
porphyria.
aPorphyria subtypes other than acute intermittent porphyria include HCP, VP, ALA dehydratase– deficiency porphyria with an identified mutation, 
and acute hepatic porphyria without an identified mutation. No patients with ALA dehydratase– deficiency porphyria were enrolled in this trial.
bThe two patients with acute hepatic porphyria without an identified mutation were considered by the trial investigator to have acute intermittent 
porphyria on the basis of biochemical analysis.
cComposite porphyria attacks are attacks requiring hospitalization, an urgent healthcare visit, or IV hemin treatment at home.
dOne patient in the placebo group did not meet inclusion criterion of ≥2 composite porphyria attacks within 6 months prior to screening (patient had 
2 attacks that were treated at home without IV hemin). This was identified as a protocol deviation.
eSymptoms were chronic if patients experienced symptoms of porphyria daily or on most days when not having an attack and were reported by 
Investigators.
fOpioid use was defined as chronic if patients reported taking them for porphyria daily or most days when not having an attack.
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F I G U R E  1   Attack frequency and hemin use with long- term givosiran treatment. A, Median AAR. †Descriptive analysis. ‡Placebo 
crossover patients receiving givosiran 2.5 mg/kg (n = 29) or 1.25 mg/kg (n = 17). B, Proportion of patients with zero attacks by 3- month 
intervals. Baseline represents 6 months prior to randomization. §One patient did not meet an inclusion criterion and was enrolled in the 
study (did not have the requisite number of attacks in the 6 months prior to randomization). Composite attacks include porphyria attacks 
requiring hospitalization, urgent healthcare visit, or intravenous hemin administration at home. 1 month = 28 days. C, Median annualized 
days of hemin use. D, Proportion of patients with zero days of hemin use. E, Proportion of patients with zero days of hemin use by 3- month 
intervals. AAR, annualized attack rate; DB, double- blind; Givo, givosiran; OLE, open- label extension; PBO, placebo
F I G U R E  2   Urinary ALA and PBG levels. A, Median ALA levels over time. B, Median PBG levels over time. OLE data for 1.25 and 
2.5 mg/kg are pooled. Reference ranges: ALA ULN, 1.47 mmol/mol Cr; PBG ULN, 0.14 mmol/mol Cr.52 ALA, delta- aminolevulinic acid; 
Cr, creatinine; DB, double- blind; OLE, open- label extension; PBG, porphobilinogen; ULN, upper limit of normal
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the givosiran group and increased by 12% in the placebo group 
(data not shown).
3.3 | Safety
AEs were reported in 90 (96%) patients; the majority of events were 
mild or moderate in severity. Severe AEs were reported in 27 (29%) 
patients. The most frequently reported AEs (in ≥10% of patients) 
were injection- site reaction (ISR), nausea, fatigue, nasopharyngitis, 
and headache (Table 2).
A total of 28 (30%) patients reported serious AEs (SAEs) during 
the study; SAEs reported in >1 patient were blood homocysteine 
increased, CKD, device breakage, pyrexia, and urinary tract infec-
tion (all n = 2) (Table S1). Three patients discontinued treatment be-
cause of SAEs considered related to givosiran by the investigators. 
One patient discontinued treatment because of abnormal results on 









Any AE 43 (94) 47 (98) 90 (96)
AEs occurring in ≥10% of patients
Injection- site reactionsa 16 (35) 19 (40) 35 (37)
Nausea 11 (24) 21 (44) 32 (34)
Fatigue 10 (22) 12 (25) 22 (23)
Nasopharyngitis 11 (24) 11 (23) 22 (23)
Headache 7 (15) 12 (25) 19 (20)
Urinary tract infection 8 (17) 9 (19) 17 (18)
Upper respiratory tract 
infection
10 (22) 6 (13) 16 (17)
Vomiting 8 (17) 7 (15) 15 (16)
Diarrhoea 7 (15) 7 (15) 14 (15)
Abdominal pain 6 (13) 7 (15) 13 (14)
Lipase increased 6 (13) 6 (13) 12 (13)
Constipation 4 (9) 6 (13) 10 (11)
Influenza 5 (11) 5 (10) 10 (11)
AEs of interest
Hepatic AEsb 8 (17) 9 (19) 17 (18)
Renal AEsc




8 (19) 13 (27) 21 (22)
Any serious AE 13 (28) 15 (31) 28 (30)
Any severe AE 14 (30) 13 (27) 27 (29)
Any AE leading to treatment 
discontinuation
2 (4) 1 (2) 3 (3)
Any AE leading to study 
withdrawal
2 (4) 1 (2) 3 (3)
Death 0 0 0
Note: Safety data from first dose of givosiran to data cutoff date (June 24, 2020).
AE, adverse event; AHP, acute hepatic porphyria; eGFR, estimated glomerular filtration rate; 
MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized MedDRA query.
aInjection- site reactions include all AEs included under the term of high- level injection- site 
reactions in MedDRA.
bHepatic AEs included any AEs within the SMQ drug- related hepatic disorders.
cRenal AEs included all AEs mapping to the SMQ chronic kidney disease.
dThis category included a subgroup of patients who had changes in serum creatinine level or eGFR 
reported as an increased blood creatinine level, a decreased eGFR, or chronic kidney disease.
TA B L E  2   Safety overview in patients 
with AHP during givosiran treatment
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described below). Two patients at one site had SAEs of blood ho-
mocysteine increased, based on laboratory assessments performed 
by the investigator that were not prespecified in the protocol. The 
elevations of homocysteine were considered medically significant 
events and considered possibly related to givosiran by the investiga-
tor. One of these patients had a concurrent SAE of hypersensitivity, 
and the other had a concurrent SAE of pancreatitis.36 Both withdrew 
from the study due to the SAEs of blood homocysteine increased. 
There were no deaths related to givosiran during the study.
Hepatic AEs were reported in 17 (18%) patients; all were mild 
or moderate in severity, the majority being serum aminotransferase 
elevations. A total of 10 patients (11%) had alanine aminotransfer-
ase (ALT) levels more than 3 times the upper limit of normal (ULN), 
of whom 3 patients (3%) had ALT levels more than 5 times ULN. 
One patient with ALT greater than 8 times the ULN, reported as an 
SAE of liver function test abnormal, discontinued treatment (due to 
a protocol- defined stopping rule) and withdrew from the study at 
the end of the double- blind period. The ALT elevations generally oc-
curred approximately 3 to 6 months after givosiran was started, and 
then resolved subsequently (Figure S10). No patients discontinued 
givosiran due to hepatic events during the OLE period.
Twenty- one patients (22%) reported renal AEs, which were 
mostly increased creatinine and/or decreased estimated glomerular 
filtration rate (eGFR); most events were mild or moderate in sever-
ity and none led to treatment discontinuation. Small decreases in 
eGFR observed early in therapy stabilized over Months 12 to 24 
(Figure S11). Some patients with pre- existing kidney disease showed 
a small, continued decrease in their eGFR. No patients discontinued 
givosiran due to renal events during the OLE period.
ISRs occurred in 37% of patients and 6% of the 2152 doses of 
givosiran given; all ISRs were mild or moderate in severity, and none 
led to discontinuation. The most common symptoms of ISRs included 
erythema, pruritus, rash, pain, and swelling at the injection site.
On laboratory evaluation, there have been no notable changes 
in haematology parameters related to givosiran. Mean values for li-
pase and amylase have remained generally stable during the study; 
however, intermittent elevations of lipase and amylase have been 
observed in some patients. The proportion of patients with shifts in 
lipase and amylase were comparable between the placebo and givo-
siran groups during the double- blind period, without any imbalances.
4  | DISCUSSION
Disease burden is substantial and treatment options are limited for 
patients with AHP who experience recurrent attacks and chronic 
symptoms between attacks.4,12,17,37 Natural history data suggest 
that up to 65% experience chronic, debilitating symptoms such as 
pain, fatigue, and nausea that negatively impact daily functioning 
and QOL.4,28,38- 40 Hemin is recommended for treatment of acute at-
tacks that do not respond to treatment with glucose and in patients 
who display neurologic symptoms or require hospitalization7,41,42; 
it is also used for prophylaxis.4,43 However, repeated prophylactic 
use of hemin may be associated with reduced efficacy, and it is as-
sociated with AEs such as venous damage and thrombophlebitis, 
coagulation abnormalities, and secondary iron overload.5,28,44,45 
Compared to placebo, givosiran treatment has been shown to have 
significant clinical efficacy and an acceptable safety profile in pa-
tients with AHP.28
Consistent with the results from the double- blind period, this 
24- month interim analysis of the ENVISION study confirms that 
long- term givosiran dosing leads to continuous and sustained reduc-
tions in AAR and hemin use, with 83% and 76% of patients being 
attack- free (continuous givosiran and placebo crossover groups, 
respectively), and 68% and 49% of patients, respectively, not re-
quiring supplemental hemin. Lower opioid use occurred against a 
background of patient- reported reduced daily worst pain (12- month 
data). Long- term givosiran dosing resulted in improvements in sev-
eral patient- reported outcomes, including physical functioning, ac-
tivities of daily living, and overall health status assessment scores. 
The SF- 12 PCS score increased by 8.9 points in the continuous givo-
siran group and 10.0 points in placebo crossover patients in the OLE. 
In other chronic diseases, a ≥2- to 5- point increase is considered a 
clinically meaningful improvement.38,39 Sustained and continuous 
improvements in the attack rate, the proportion of patients who re-
mained attack- free, and patient- reported outcomes were associated 
with sustained lowering of ALA and PBG levels, the toxic heme inter-
mediates considered causal for disease manifestations.2,11
During the OLE period, the protocol was amended to assess the 
efficacy and safety of a lower dose of givosiran (1.25 mg/kg). Results 
demonstrated a trend toward greater reductions in AAR, urinary 
ALA and PBG levels, and hemin use in placebo crossover patients 
treated with givosiran 2.5 mg/kg once monthly, compared with 
those treated with givosiran 1.25 mg/kg once monthly (Alnylam, 
data on file). Consistent with this observation, approximately half of 
the patients assigned to the 1.25 mg/kg dosing regimen (including 
those in the placebo crossover group and the continuous givosiran 
group) had inadequate disease control and required dose escalation 
to 2.5 mg/kg. Both dosing regimens had acceptable safety profiles. 
Thus, the recommended dosing regimen for givosiran is 2.5 mg/kg 
once monthly.
The key safety findings of this 24- month interim analysis were 
consistent with those observed during the 6- month double- blind 
period28 and from the phase 2 OLE study, in which patients were 
treated with givosiran for ≥36 months.46 Elevations in serum amino-
transferase levels occurred in some patients, primarily 3 to 5 months 
after initiation of the trial regimen; most resolved with continued 
dosing. CKD is a long- term complication of AHP,18 and one- third of 
patients in ENVISION had reduced eGFR (<60 mL/min/1.73 m2) at 
baseline. During treatment with givosiran, small (mostly reversible) 
decreases in eGFR were observed early in therapy and generally 
stabilized by Months 12 to 24. Renal function should be monitored 
during givosiran treatment, as clinically indicated.
Elevations of blood homocysteine have been reported in patients 
with AHP, with a correlation of higher levels in those with greater 
disease activity.36,47- 49 As 2 SAEs of blood homocysteine increases 
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were observed in the present ENVISION study,36 analyses of blood 
homocysteine levels were performed on exploratory samples, which 
included levels collected before, during, and after givosiran treat-
ment. During these analyses, blood homocysteine levels were also 
noted to be increased compared with available baseline levels.50,51 
Blood homocysteine levels increased in all patients in one analysis 
(9/9 patients) and in most patients in the second analysis (14/15 pa-
tients).50,51 The degree of homocysteine elevation varied among pa-
tients.50,51 The long- term consequences of homocysteine elevations 
in patients with AHP are unknown. Additional work on the possible 
implications is needed.
The study is limited by the relatively small number of patients in 
the study population. However, the ongoing ENVISION study is the 
largest intervention study to date for this rare disease.
The 24- month data from this phase 3 study show that long- term 
dosing with givosiran is well tolerated and provides sustained and 
continuous benefit to patients with AHP, as reflected by a durable 
reduction in frequency of attacks, hemin use to treat attacks, lev-
els of toxic heme intermediates ALA and PBG, daily pain, and opioid 
use. Givosiran treatment was also associated with improvement in 
assessments of physical functioning and QOL.
E THIC S APPROVAL S TATEMENT
The study was approved by central and local institutional review 
boards or ethics committees and was conducted in accordance 
with Good Clinical Practice guidelines and the provisions of the 
Declaration of Helsinki.
ACKNOWLEDG EMENTS
The sponsor was involved in the design and conduct of the study; 
collection, management, analysis, and interpretation of the data; 
preparation, review, or approval of the manuscript; and decision to 
submit the manuscript for publication.
CONFLIC T OF INTERE S T
Dr Ventura reported receiving advisory board fees and lecture 
fees from Alnylam Pharmaceuticals and advisory board fees from 
Recordati Rare Diseases. Dr Bonkovsky reported receiving grant 
support and financial support, paid to Wake Forest University 
School of Medicine, from Alnylam Pharmaceuticals, Gilead 
Sciences, and Mitsubishi Tanabe, NA; consulting fees from Alnylam 
Pharmaceuticals, Disc Medicine, Eiger Biopharmaceuticals, 
Protagonist Therapeutics, and Recordati Rare Diseases. Dr 
Gouya reported receiving travel support and financial support 
from Alnylam Pharmaceuticals. Dr Aguilera- Peiró reported re-
ceiving advisory board fees from Alnylam Pharmaceuticals. Dr 
Bissell reported receiving financial support, paid to University 
of California, San Francisco, from Alnylam Pharmaceuticals. Dr 
Stein reported receiving consulting fees, registration reimburse-
ment, and financial support, paid to King's College Hospital, 
from Alnylam Pharmaceuticals. Dr Balwani reported receiving 
grant support, consulting fees, advisory board fees, and lecture 
fees from Alnylam Pharmaceuticals, advisory board fees from 
Recordati Rare Diseases, grant support and advisory board fees 
from Mitsubishi Tanabe, and advisory board fees from Alexion, 
Genzyme/Sanofi, and Takeda. In addition, Mount Sinai faculty 
are named Co- Inventors with Alnylam on a patent related to 
the development of givosiran, the study drug. The Icahn School 
of Medicine at Mount Sinai receives payments related to this 
patent from Alnylam, and a portion of these payments are also 
distributed to faculty and other co- inventors. Dr Anderson re-
ported receiving grant support and consulting fees from Alnylam 
Pharmaceuticals, Recordati Rare Diseases, and Mitsubishi Tanabe, 
and consulting fees from Moderna Therapeutics. Dr Parker re-
ported receiving financial support, paid to University of Utah, 
from Alnylam Pharmaceuticals. Dr Kuter reported receiving grant 
support and consulting fees from Actelion (Syntimmune), Agios, 
Alnylam Pharmaceuticals, Amgen, Argenx, Bristol Myers Squibb, 
Protalix, Rigel, and Takeda (Bioverativ), grant support from Kezar 
and Principia, and consulting fees from Caremark, Daiichi Sankyo, 
Dova, Kyowa- Kirin, Merck Sharp Dohme, Momenta, Novartis, 
Pfizer, Platelet Disorder Support Association, Principia, Protalix, 
Sanofi, Genzyme, Shionogi, Shire, UCB, Up- To- Date, and Zafgen. 
Dr Monroy reported receiving advisory board fees from Alnylam 
Pharmaceuticals. Dr Oh reported lecture fees from Merck, Pfizer, 
and Genzyme. Dr Ritchie reported receiving consulting fees, paid to 
the University of Alberta from Alnylam, Takeda, CSL Behring, and 
BioCryst, and grant support from CSL Behring and OctaPharma. 
Drs. Ko, Hua, and Sweetser reported being employed by and 
owning stock and stock options in Alnylam Pharmaceuticals. Dr 
Sardh reported receiving grant support and personal fees, paid to 
Karolinska Institutet, from Alnylam Pharmaceuticals.
AUTHORS CONTRIBUTIONS
All authors had full access to all of the data in the study and take re-
sponsibility for the integrity of the data and the accuracy of the data 
analysis. Concept and design: Anderson, Balwani, Bissell, Bonkovsky, 
Gouya, Sardh. Acquisition, analysis, or interpretation of data: All au-
thors. Drafting of the manuscript: Ko, Hua. Critical revision of the 
manuscript for important intellectual content: All authors. Statistical 
analysis: Hua. Supervision: Sardh, Ventura.
ADDITIONAL CONTRIBUTIONS
Joseph Bloomer, MD (University of Alabama, USA), Daphne 
Vassiliou, MD, PhD (Karolinska University Hospital, Sweden), 
Elisabeth Minder, MD (Stadtspital Triemli, Switzerland), John 
Phillips, PhD (University of Utah School of Medicine, USA), David 
Rees, MD (King's College Hospital, UK), Ashwani Singal, MD 
(University of Alabama, USA) and Bruce Wang, MD (University 
of California, USA) also contributed to the design and concept 
of the study. Editorial assistance was provided by Jennifer LS 
Willoughby (PhD) of Alnylam Pharmaceuticals, Cambridge, MA, 
USA. Medical writing services were provided by Colette Szarka 
(MPhil) of Adelphi Communications Ltd, Macclesfield, UK, and 
by Michael Morren (RPh, MBA) of Peloton Advantage, LLC, an 
OPEN Health company, Parsippany, NJ, USA, in accordance with 
     |  11VENTURA ET Al
Good Publication Practice (GPP3) guidelines, and were funded by 
Alnylam Pharmaceuticals, Cambridge, MA, USA.
TRIAL REG IS TR ATION NUMBER
ClinicalTrials.gov, NCT03338816.
PATIENT CONSENT S TATEMENT
All patients provided written informed consent.
DATA AVAIL ABILIT Y S TATEMENT
De- identified individual participant data that support these results 
will be made available in a secure- access environment 12 months 
after study completion and when the product and indication have 
been approved for no less than 12 months in the US and the EU. 
Access will be provided contingent upon the approval of a research 
proposal and the execution of a data sharing agreement.
ORCID
Paolo Ventura  https://orcid.org/0000-0002-5026-6400 
R E FE R E N C E S
 1. Puy H, Gouya L, Deybach JC. Porphyrias. The Lancet. 
2010;375(9718):924- 937.
 2. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and 
treatment. Blood. 2012;120(23):4496- 4504.
 3. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in 
the USA: features of 108 subjects from porphyrias consortium. Am 
J Med. 2014;127(12):1233- 1241.
 4. Gouya L, Ventura P, Balwani M, et al. EXPLORE: a prospective, mul-
tinational, natural history study of patients with acute hepatic por-
phyria with recurrent attacks. Hepatology. 2019;71(5):1546- 1558.
 5. Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyr-
ias: review and recent progress. Hepatol Commun. 2019;3(2):193- 206.
 6. Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyr-
ias: recommendations for evaluation and long- term management. 
Hepatology. 2017;66(4):1314- 1322.
 7. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations 
for the diagnosis and treatment of the acute porphyrias. Ann Intern 
Med. 2005;142(6):439- 450.
 8. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 
2017;377(9):862- 872.
 9. Ramanujam VM, Anderson KE. Porphyria diagnostics- part 1: 
a brief overview of the porphyrias. Curr Protoc Hum Genet. 
2015;86(1):11- 26.
 10. Pischik E, Kauppinen R. An update of clinical management of acute 
intermittent porphyria. Appl Clin Genet. 2015;8:201- 214.
 11. Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical fea-
tures of the acute hepatic porphyrias (AHPs). Mol Genet Metab. 
2019;128(3):213- 218.
 12. Stein PE, Badminton MN, Rees DC. Update review of the acute por-
phyrias. Br J Haematol. 2017;176(4):527- 538.
 13. Harper P, Sardh E. Management of acute intermittent porphyria. 
Expert Opin Orphan Drugs. 2014;2(4):349- 368.
 14. Rad N, Beydoun SR. Porphyria- induced recurrent quadriplegia mis-
diagnosed as Guillain- Barré syndrome. US Neurol. 2020;16(1):66- 69.
 15. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The 
incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 
2013;36(5):849- 857.
 16. Schmitt C, Lenglet H, Yu A, et al. Recurrent attacks of acute hepatic 
porphyria: major role of the chronic inflammatory response in the 
liver. J Intern Med. 2018;284(1):78- 91.
 17. Simon A, Pompilus F, Querbes W, et al. Patient perspective on acute 
intermittent porphyria with frequent attacks: a disease with inter-
mittent and chronic manifestations. Patient. 2018;11(5):527- 537.
 18. Pallet N, Mami I, Schmitt C, et al. High prevalence of and potential 
mechanisms for chronic kidney disease in patients with acute inter-
mittent porphyria. Kidney Int. 2015;88(2):386- 395.
 19. Stewart MF. Review of hepatocellular cancer, hypertension 
and renal impairment as late complications of acute porphyria 
and recommendations for patient follow- up. J Clin Pathol. 
2012;65(11):976- 980.
 20. Andersson C, Bjersing L, Lithner F. The epidemiology of hepato-
cellular carcinoma in patients with acute intermittent porphyria. J 
Intern Med. 1996;240(4):195- 201.
 21. Willandt B, Langendonk JG, Biermann K, et al. Liver fibrosis as-
sociated with iron accumulation due to long- term heme- arginate 
treatment in acute intermittent porphyria: a case series. JIMD Rep. 
2016;25:77- 81.
 22. Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome 
PN. Liver transplantation from donors with acute intermittent por-
phyria. Ann Intern Med. 2011;154(8):571- 572.
 23. Recordati Rare Disease Inc. US Prescribing Information: 
PANHEMATIN (hemin for injection). 2017.
 24. Alnylam Pharmaceuticals Inc. GIVLAARI Highlights of Prescribing 
Information. 2019. https://www.acces sdata.fda.gov/drugs atfda_
docs/label/ 2019/02121 94s00 0lbl.pdf
 25. Alnylam Pharmaceuticals Inc. Alnylam announces approval of 
GIVLAARI® (givosiran) in Brazil for the treatment of acute hepatic 
porphyria (AHP) in adults [press release]. July 20, 2020.
 26. Alnylam Pharmaceuticals Inc. GIVLAARI™ Givosiran Injection 
Solution 189 mg/mL givosiran (as givosiran sodium), subcutane-
ous injection A16AX16. Various alimentary tract and metabolism 
products. 2020. https://www.alnyl am.ca/Canad a- Givla ari- Produ 
ct- Monog raph- ENG.pdf
 27. Alnylam Pharmaceuticals Inc. GIVLAARI Summary of Product 
Characteristics. 2020. https://www.ema.europa.eu/en/docum ents/
produ ct- infor matio n/givla ari- epar- produ ct- infor mation_en.pdf
 28. Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi ther-
apeutic givosiran for acute intermittent porphyria. N Engl J Med. 
2020;382(24):2289- 2301.
 29. Chan A, Liebow A, Yasuda M, et al. Preclinical development of a 
subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic 
porphyrias using circulating RNA quantification. Mol Ther Nucleic 
Acids. 2015;4:e263.
 30. Sardh E, Harper P, Balwani M, et al. Phase 1 trial of an RNA in-
terference therapy for acute intermittent porphyria. N Engl J Med. 
2019;380(6):549- 558.
 31. Vassiliou D, Sardh E, Harper P, et al. A drug- drug interaction 
study to investigate the effect of givosiran on the activity of 5 
major drug metabolizing CYP450 enzymes in subjects with acute 
intermittent porphyria who are chronic high excreters. Presented 
at: International Congress on Porphyrins and Porphyrias; Milan, 
Italy.
 32. Anderson KE, Bissell DM, Bonkovsky H, et al. Phase 1/2 and open 
label extension studies of givosiran, an investigational RNA inter-
ference (RNAi) therapeutic, in patients with acute intermittent por-
phyria. Presented at: American Association for the Study of Liver 
Diseases (AASLD); San Francisco, CA, USA.
 33. Cleeland CS. The Brief Pain Inventory User Guide. 2009. https://
www.mdand erson.org/docum ents/Depar tment s- and- Divis ions/
Sympt om- Resea rch/BPI_UserG uide.pdf
12  |     VENTURA ET Al
 34. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment 
of fatigue severity in cancer patients: use of the Brief Fatigue 
Inventory. Cancer. 1999;85(5):1186- 1196.
 35. Ware J Jr, Kosinski M, Keller SD. A 12- item short- form health sur-
vey: construction of scales and preliminary tests of reliability and 
validity. Med Care. 1996;34(3):220- 233.
 36. Petrides PE, Klein M, Schuhmann E, et al. Severe homocysteinemia 
in two givosiran- treated porphyria patients: is free heme deficiency 
the culprit? Ann Hematol. 2021;100:1685- 1693.
 37. Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences 
and concerns of patients with recurrent attacks of acute hepatic por-
phyria: a qualitative study. Mol Genet Metab. 2016;119(3):278- 283.
 38. Clement ND, MacDonald D, Simpson AH. The minimal clinically 
important difference in the Oxford knee score and Short Form 
12 score after total knee arthroplasty. Knee Surg Sports Traumatol 
Arthrosc. 2014;22(8):1933- 1939.
 39. Parker SL, Mendenhall SK, Shau DN, et al. Minimum clinically im-
portant difference in pain, disability, and quality of life after neural 
decompression and fusion for same- level recurrent lumbar steno-
sis: understanding clinical versus statistical significance. J Neurosurg 
Spine. 2012;16(5):471- 478.
 40. Naik H, Overbey JR, Desnick RJ, et al. Evaluating quality of life tools 
in North American patients with erythropoietic protoporphyria and 
X- linked protoporphyria. JIMD Rep. 2019;50(1):9- 19.
 41. Stölzel U, Doss MO, Schuppan D. Clinical guide and update on por-
phyrias. Gastroenterology. 2019;157(2):365- 381.e364.
 42. Harper P, Wahlin S. Treatment options in acute porphyria, por-
phyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat 
Options Gastroenterol. 2007;10(6):444- 455.
 43. Yarra P, Faust D, Bennett M, Rudnick S, Bonkovsky HL. Benefits of 
prophylactic heme therapy in severe acute intermittent porphyria. 
Mol Genet Metab Rep. 2019;19: 100450.
 44. Marsden JT, Guppy S, Stein P, et al. Audit of the use of regular haem 
arginate infusions in patients with acute porphyria to prevent re-
current symptoms. JIMD Rep. 2015;22:57- 65.
 45. Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, 
Newsome PN. Liver transplantation for acute intermittent por-
phyria is complicated by a high rate of hepatic artery thrombosis. 
Liver Transpl. 2012;18(2):195- 200.
 46. Stein P, Rees D, Anderson K, et al. A phase 1/2 open label extension 
study of givosiran, an investigational RNAi therapeutic, in patients 
with acute intermittent porphyria. J Hepatol. 2020;73:S553.
 47. To- Figueras J, Lopez RM, Deulofeu R, Herrero C. Preliminary re-
port: hyperhomocysteinemia in patients with acute intermittent 
porphyria. Metabolism. 2010;59(12):1809- 1810.
 48. Ventura P, Corradini E, Di Pierro E, et al. Hyperhomocysteinemia in 
patients with acute porphyrias: a potentially dangerous metabolic 
crossroad? Eur J Intern Med. 2020;79:101- 107.
 49. To- Figueras J, Wijngaard R, García- Villoria J, et al. Dysregulation 
of homocysteine homeostasis in acute intermittent porphyria pa-
tients receiving heme arginate or givosiran. J Inherit Metab Dis. 
2021;44(4):961- 971.
 50. Ricci A, Marcacci M, Cuoghi C, Pietrangelo A, Ventura P. 
Hyperhomocysteinemia in patients with acute porphyrias: 
a possible effect of ALAS1 modulation by siRNAm therapy 
and its control by vitamin supplementation. Eur J Intern Med. 
2021;92:121- 123.
 51. Vassiliou D, Sardh E. Homocysteine elevation in givosiran treat-
ment: suggested ALAS1 siRNA effect on cystathionine beta- 
synthase. J Intern Med. 2021;290(4):928- 930.
 52. Agarwal S, Habtemarium B, Xu Y, Simon AR, Kim JB, Robbie GJ. 
Normal reference ranges for urinary δ- aminolevulinic acid and por-
phobilinogen levels. JIMD Rep. 2021;57(1):85- 93.
SUPPORTING INFORMATION
Additional supporting information may be found in the online ver-
sion of the article at the publisher’s website.
How to cite this article: Ventura P, Bonkovsky HL, Gouya L, 
et al; for the ENVISION Investigators. Efficacy and safety of 
givosiran for acute hepatic porpfhyria: 24- month interim 
analysis of the randomized phase 3 ENVISION study. Liver 
Int. 2021;00:1– 12. doi:10.1111/liv.15090
